Teva Specialty & Biosimilar Pipeline

By development stage – as of July 15, 2022


Teva’s Global R&D organization helps propel the company’s mission to be a global leader in generics and biopharmaceuticals. From early development to commercial launch of small molecules, novel biologics and biosimilars, our uniquely integrated “One Teva” drug development model combines our strength in generics with our knowledge of innovative drug development.  We understand the many ways that health impacts people’s lives, and will continue to invest in new breakthrough treatments, offer innovative solutions, and find new ways to extend and expand patient care beyond medicine.

Technology Platforms:

Novel Biologics
Small Molecules
Digital Respiratory
Biosimilars

Under Regulatory Review

Biosimilar to Humira®
(adalimumab) 01

Risperidone LAI Schizophrenia

Biosimilar to Lucentis® (ranibizumab) 05

Pre Submission

Digihaler®
(budesonide and formoterol
fumarate dihydrate)
(EU)

QVAR® Digihaler® 
(beclomethasone dipropionate HFA)
(US)

Phase 3

Biosimilar to Eylea® (aflibercept)

Fasinumab 02
Osteoarthritic Pain

Deutetrabenazine 03
Dyskinesia in Cerebral Palsy

Biosimilar to Prolia® (denosumab)

Biosimilar to Stelara® (Ustekinumab) 01

Biosimilar to Xolair® (omalizumab)

Phase 2

TEV-48574
Inflammatory Bowel Disease

Phase 1

TV-44749
Schizophrenia

TEV-53408
Gastrointestinal

TEV- 56286 04
Multiple System Atrophy

TEV-56248
Respiratory

Pre-clinical

TEV-46000
Neuroscience

TEV-56278
Oncology

TEV-56192
Respiratory

TEV-56279
Pain

TV-48438
Schizophrenia

TEV-56287 04
Parkinson’s Disease

TEV-56285

TEV-54142

TEV-56194

TEV-56191

TEV-56261

TEV-56282 01

TEV-56284 01

TEV-56289

Novel Biologics
Small Molecules
Digital Respiratory
Biosimilars

Download a PDF version of Teva Specialty and Biosimilar Pipeline

Download PDF

Teva specialty and biosimilar pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.

Pipeline is current as of July 15, 2022

  1. Back to contents.

    In collaboration with Alvotech for the US market.

  2. Back to contents.

    In collaboration with Regeneron.

  3. Back to contents.

    This use is investigational.

  4. Back to contents.

    In collaboration with MODAG.

  5. Back to contents.

    In collaboration with BioEq in UK (marketed as ONGAVIA®), Europe (under regulatory review) and Canada (expected submission in late 2022).